

T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



25<sup>th</sup> January 2024

| Mumbai – 400001<br>Scrip Code: BSE – AJANTPHARM 532331 | Bandra (East), Mumbai – 400 051<br>Scrip Code: NSE AJANTPHARM EQ |
|--|--|
| Dalal Street,  | C/1, G Block, Bandra Kurla Complex,                              |
| Phiroze Jeejeebhoy Towers                              | Exchange Plaza, 5 <sup>th</sup> Floor, Plot no.                  |
| BSE LIMITED  | National Stock Exchange of India,                                |

## **Ref.:** Intimation under Regulation 29(1)(e) of the Listing Regulations

## **Subject:** Notice of the meeting of Board of Directors to consider dividend on equity shares of the company

Dear Sirs/Madam,

This is with reference to our letter dated 19<sup>th</sup> January 2024, informing about the Board meeting scheduled on Wednesday, 31<sup>st</sup> January 2024 to *inter-alia* consider and take on record the unaudited financial results for the third quarter ended 31<sup>st</sup> December 2023.

Pursuant to Regulation 29(1)(e) of the Listing Regulations, we hereby inform that, at the aforesaid Board Meeting, the Board of Directors will also consider:

- a. declaration of 2<sup>nd</sup> interim dividend for the financial year ending 31<sup>st</sup> March 2024;
- b. fixation of Thursday, 8<sup>th</sup> Dec 2024 as the Record Date for the payment of 2<sup>nd</sup> interim dividend, if declared.

You are requested to please take a note of the above and disseminate to all concerned.

Thanking you,

Yours faithfully,

**Gaurang Shah** *VP – Legal & Company Secretary* 

Page 1 of 1